Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Triple Negative Breast Neoplasms 2 Recurrence 1 Neoplasms 1 Multiple Myeloma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lymphoma 1 Locally Advanced (Inoperable) or Metastatic Breast Cancer 1 Hematologic Neoplasms 1 Carcinosarcoma 1 Carcinoma, Endometrioid 1 Breast Neoplasms 1 Advanced Solid Malignancy, 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Advanced Solid Malignancy, × capivasertib × Clear all

NCT01895946 2016-05-25

OAK

AstraZeneca

Phase 1 Completed

33 enrolled 14 charts

Advanced Solid Malignancy,

Data powered by HemOnc (CC BY 4.0) Colophon ⚡